Moody’s lowers Eli Lilly outlook to ‘negative’
Moody's Investors Service on Friday lowered its rating outlook on drugmaker Eli Lilly and Co. to "negative"
from "table" due in part to the looming expiration of patents protecting key drugs from generic competition.